Tetra BioPharma Inc (OTCMKTS:TBPMF) Updates Management on the progress of Tetra Natural Health

Tetra BioPharma Inc (OTCMKTS:TBPMF) recently provided the management update on its undertakings to promote one of its topical products, Awaye™, and commercialize other natural health drugs and non-prescription products across the region of North America. Furthermore, Tetra Bio-Pharma (TNH) is planning to enter into a distribution merger to enhance the commercialization of its over-the-counter (OTC) pain killer drugs portfolio.

The company intends to commercialize a portfolio of OTC products that are already at an advanced stage; hence, no further capital investment or clinical research is necessarily required. Additionally, Tetra has verified that the development of the two OTC DIN products is at its final stage. One of the drugs will be used to treat hemorrhoids while the second one is a pain relief for aches, joints, and muscle pains ranging from backache, bruises, rheumatic, arthritic, and ligaments.

Market Expansion into Canada and USA

The company further stated that the non-prescription drug applications are ready for the market, and plans are underway to submit to Health Canada before the end of the month. Also, TNH plans to launch the same products into the US market before the end of 2020. Currently, the company is developing a manufacturing plant and has applied for the National Drug Code (NDC) from the US Food and Drug Administration (FDA).

Additional Drug Portfolio

Besides, TNH has extra non-prescription drug product line specifically for Canada and US OTC drug markets. These OTC drugs contain an aspect of beta-caryophyllene and, therefore, may not require a prior clinical trial to sustain its DIN application. OTC drugs are used explicitly for self-care therapies.

Other developments in the company include a strong relationship with Azevedos, one of the oldest Pharmaceutical companies in Portugal, with operations in Mozambique, Tunisia, and other regions globally. Further, TNH has invested in state-of-the-art manufacturing facilities, infrastructure, and human resources. The company’s focus on natural health products has enabled it to prosper and become famous in the European markets and worldwide. The company is planning to enter into partnerships with other natural product firms for commercialization and distribution of natural health products.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Considering Lifesci Public Relations And Lifesci Advisors For Its Strategic Partners Positions Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Gets Shareholder Greenlight To Acquire Panag Pharma Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Advances Its European Drug Registration Plans Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Partners With Genacol Canada Corporation To Offer Cannabinoid Treatments To Self-Care Market In Canada Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Adds Extension To North Bud Farms Inc; Gets Approval From Health Canada For PPP001 Drug

Pin It on Pinterest